The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose Diet
Abstract
Recent evidence suggests that treatment with mineralocorticoid receptor antagonist suppressed local inflammation in vascular tissues or cardiomyocytes; therefore, we examined the effect of spironolactone on glucose and lipid metabolism in a mouse model with diet-induced diabetes and nonalcoholic fatty liver disease. C57BL/6 mice were fed either the control diet, 60% fat diet with 30% fructose water (HFFD), or HFFD with spironolactone for 8 wk. HFFD mice demonstrated apparent phenotypes of metabolic syndrome, including insulin resistance, hypertension, dyslipidemia, and fatty liver. Although treatment with spironolactone did not affect the increased calorie intake and body weight by HFFD, the increments of epididymal fat weight, blood pressure, serum triglyceride, free fatty acids, leptin, and total cholesterol levels were significantly suppressed. Elevation of blood glucose during glucose and insulin tolerance tests in HFFD mice was significantly lowered by spironolactone. Notably, increased glucose levels during pyruvate tolerance test in HFFD mice were almost completely ameliorated to control levels by the treatment. Staining with hematoxylin-eosin (HE) and Oil-red-O demonstrated marked accumulation of triglycerides in the centrilobular part of the hepatic lobule in HFFD mice, and these accumulations were effectively improved by spironolactone. Concomitantly HFFD feeding markedly up-regulated hepatic mRNA expression of proinflammatory cytokines (TNFα, IL-6, and monocyte chemoattractant protein-1), gluconeogenic gene phosphoenolpyruvate carboxykinase, transcription factor carbohydrate response element binding protein, and its downstream lipogenic enzymes, all of which were significantly suppressed by spironolactone. These results indicate that inhibition of mineralocorticoid receptor might be a beneficial therapeutic approach for diet-induced phenotypes of metabolic syndrome and fatty liver.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Obesity-induced inflammatory changes in adipose tissue
Wellen, K. E., & Hotamisligil, G. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320514 · Cited by 1,823
Obesity, Inflammation, and Insulin Resistance
Shoelson, S. E., Herrero, L., & Naaz, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.059 · Cited by 1,806
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
AGA technical review on nonalcoholic fatty liver disease
Sanyal, A. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.36572 · Cited by 1,072
Dhingra, R., Sullivan, L., Jacques, P. F., Wang, T. J., Fox, C. S., Meigs, J. B., D’Agostino, R. B., Gaziano, J. M., & Vasan, R. S. (2007) · Circulation · doi:10.1161/circulationaha.107.689935 · Cited by 918
Fructose consumption as a risk factor for non-alcoholic fatty liver disease
Ouyang, X., Cirillo, P., Sautin, Y., McCall, S., Bruchette, J. L., Diehl, A. M., Johnson, R. J., & Abdelmalek, M. F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.02.011 · Cited by 863
Our new president—Jon I. Isenberg, M.D
Boland, C. R., & Yamada, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.24057 · Cited by 629
Cited by
Animal models of nonalcoholic fatty liver disease
Hebbard, L., & George, J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.191 · Cited by 499
Rodent Models for Metabolic Syndrome Research
Panchal, S. K., & Brown, L. (2011) · BioMed Research International · doi:10.1155/2011/351982 · Cited by 408
Jaisser, F., & Farman, N. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011106 · Cited by 327
Targeting inflammation in metabolic syndrome
Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.017 · Cited by 287
Laboratory animals as surrogate models of human obesity
Nilsson, C., Raun, K., Yan, F.-F., Larsen, M. O., & Tang-Christensen, M. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.203 · Cited by 275
Metadata
- Authors
- Wada, T., Kenmochi, H., Miyashita, Y., Sasaki, M., Ojima, M., Sasahara, M., Koya, D., Tsuneki, H., & Sasaoka, T.
- Affiliations
- University of Toyama (JP)
- Kanazawa Medical University (JP)
- Corresponding author
- Sasaoka, Toshiyasu
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2010-03-08
- Volume
- 151
- Issue
- 5
- Pages
- 2040-2049
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2097868433
- Cited by
- 189
- References
- 44
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 6 · 2023: 6 · 2022: 15 · 2021: 16 · 2020: 14 · 2019: 18 · 2018: 14 · 2017: 10 · 2016: 10 · 2015: 16 · 2014: 10 · 2013: 20 · 2012: 11
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Toyama
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- spironolactone, mineralocorticoid receptor antagonism, non-alcoholic fatty liver disease, hepatic steatosis, glucose metabolism, lipid metabolism, metabolic syndrome, insulin resistance, high-fat high-fructose diet, gluconeogenesis, liver inflammation, inflammatory cytokines, ChREBP, dyslipidemia
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Mineralocorticoid Receptor Antagonists, Animals, Body Weight, Cells, Cultured, Dietary Carbohydrates, Dietary Fats, Fatty Liver, Gluconeogenesis, Glucose, Humans, Inflammation, Insulin, Lipids, Male, Mice, Inbred C57BL, Spironolactone, Transcription Factors, Trans-Activators, Gene Expression, Rats, Sprague-Dawley, Reverse Transcriptase Polymerase Chain Reaction, Lipid Metabolism, Mice, Rats, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose Diet. https://app.cochat.ai/papers/10.1210/en.2009-0869
- The paper
- Wada, T., Kenmochi, H., Miyashita, Y., Sasaki, M., Ojima, M., Sasahara, M., Koya, D., Tsuneki, H., & Sasaoka, T. (2010). Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose Diet. Endocrinology. https://doi.org/10.1210/en.2009-0869
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.